Recent Investment Analysts’ Ratings Changes for Marinus Pharmaceuticals (MRNS)

A number of firms have modified their ratings and price targets on shares of Marinus Pharmaceuticals (NASDAQ: MRNS) recently:

• 4/17/2024 – Marinus Pharmaceuticals had its price target lowered by analysts at Truist Financial Co. from $25.00 to $10.00. They now have a “buy” rating on the stock.
• 4/16/2024 – Marinus Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Robert W. Baird.
• 4/16/2024 – Marinus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
• 4/15/2024 – Marinus Pharmaceuticals had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $3.00 price target on the stock, down previously from $24.00.
• 4/10/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
• 3/26/2024 – Marinus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
• 3/7/2024 – Marinus Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
• 3/6/2024 – Marinus Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 3/6/2024 – Marinus Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $24.00 price target on the stock.
• 3/6/2024 – Marinus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.

Marinus Pharmaceuticals Stock Performance

NASDAQ MRNS opened at $1.41 on Friday. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. Marinus Pharmaceuticals, Inc. has a 1 year low of $1.11 and a 1 year high of $11.26. The company has a market capitalization of $77.45 million, a PE ratio of -0.54 and a beta of 0.91. The company has a fifty day moving average of $8.55 and a two-hundred day moving average of $8.40.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. During the same quarter in the prior year, the company earned ($0.76) EPS. As a group, analysts expect that Marinus Pharmaceuticals, Inc. will post -2.37 earnings per share for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Large investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Marinus Pharmaceuticals by 1,887.9% in the first quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 4,210 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the third quarter worth about $38,000. Quantbot Technologies LP acquired a new stake in shares of Marinus Pharmaceuticals during the first quarter worth about $40,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Marinus Pharmaceuticals during the second quarter worth about $45,000. Finally, Jane Street Group LLC acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth about $47,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.